FDA Clears Over-the-Counter Abbott Glucose Monitors

The Food and Drug Administration (FDA) approved two Abbott products, allowing the company to sell over-the-counter continuous glucose monitors (CGM).

Libre Rio will be offered to patients with Type 2 diabetes who do not take insulin while Lingo is for maintaining health.

Abbott Launches Two OTC Glucose Monitors

In a press release, Abbott Laboratories announced that the FDA has approved its two new devices. The company currently has existing CGMs that are used by six million patients around the world.

Abbott shared that there are 38.4 million diabetes patients in the U.S., who will benefit from their CGMs. This type of device is used to poke through the skin to track a person's real-time glucose level.

Libre Rio is targeted towards diabetes Type 2 patients who do not take insulin. The device is designed for people who manage their health through lifestyle modifications.

Abbott Introduces CGM for Non-Diabetic

The other device, called Lingo, was created to cater consumers who are keen to improve their health and wellness. The users of the device must wear the biosensor on their upper arm in 14 days at a time.

Users can track their glucose levels through the coaching app on their smartphone. In addition, a customized coaching based on their data can be accessed.

Lingo is designed to help customers manage their metabolism and improve their overall wellness by analyzing their glucose level and guiding them.

"There is no one-size-fits all approach for glucose monitoring, which is why we've designed different products for different people - all based on the same world-leading biowearable technology," said Lisa Earnhardt, executive vice president and group president of Abbott's medical devices business.